KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR ...
Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced ...
The live call may be accessed by dialing (800) 579-2543 for domestic callers and (785) 424-1789 for international callers and entering the conference ID: KURAQ4. A live webcast and archived replay of ...
Kura Oncology (NASDAQ:KURA – Get Free Report) is anticipated to issue its quarterly earnings data after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings ...
FTI = Farnesyl transferase inhibitor; Grb-2 = Growth factor receptor-bound protein 2; Hck = Hemopoietic cell kinase; JAK = Janus kinase; Lyn = V-yes-1 Yamaguchi sarcoma viral related oncogene ...
Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors ...
KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib ...
KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果